The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMP.L Regulatory News (AMP)

  • There is currently no data for AMP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

New Suits Filed and New Debt Facilites

21 Nov 2011 08:42

RNS Number : 4373S
Amphion Innovations PLC
21 November 2011
 



Amphion Subsidiary Files Additional Patent Infringement Suits

For Its Object-Oriented Software/ Relational Database Patent

New Debt Facility

 

London and New York 21 November 2011 - Amphion Innovations plc (LSE: AMP) announces that DataTern, Inc., owner of U.S. Patent No. 6,101,502 ("the '502 patent") has filed patent infringement cases against a number of companies in the United States District Court for the District of Massachusetts, asserting infringement of the '502 patent. The '502 patent is directed to novel and groundbreaking methods and systems for facilitating interaction between object-oriented software programmes and relational databases. As such, the patented technology has become fundamental to the development of numerous enterprise software applications, including business intelligence and data mining products.

 

According to DataTern's Chief Executive Officer, John Caruso, "numerous companies have recognized the importance of the patented technology to their software products and systems and have thus licensed the technology. We want to make sure to protect our licensees and the substantial investment made in the technology by stopping those who would use our patented technology without permission."

 

DataTern, a wholly-owned subsidiary of Amphion Innovations plc., fosters innovation by helping companies develop and commercialise promising technologies, including in the IT and healthcare sectors. DataTern is represented by McCarter & English LLP in Boston.

 

Amphion also today announces it has agreed additional unsecured loan financing of $500,000 from R. James Macaleer, Chairman of Amphion, who is also interested in 17.31% of the issued share capital of the Company. The loan is repayable on 15 February 2012 and carries an interest rate of 7% per annum.

 

Furthermore, as part of the new debt facility agreement, outstanding loans to Mr Macaleer as announced on 15 April 2011 and 9 December 2010 which became payable on 31 January 2012 for a total of $1 million have been extended until 31 December 2012 and a loan of $2 million dollars which became payable at 31 December 2012 has been extended to 31 December 2013. All loans will carry the interest rate of 7% per annum.

This transaction is deemed a related party transaction for the purposes of the AIM Rules. As a result, the Independent Directors consider, having consulted with the Company's nominated adviser, that the terms of the transaction are fair and reasonable insofar as its shareholders are concerned.

 

For further information please contact:

DataTern Inc.

John Caruso +1 212 210 6248

 

McCarter & English LLP

Lee Carl Bromberg +1 617 449 6538

Erik Paul Belt + 1 617 449 6506

 

Amphion Innovations plc

Charlie Morgan +1 212 210 6224

 

Cardew Group

Tim Robertson +44 20 7930 0777

 

Seymour Pierce Limited (Nominated Adviser)

Freddie Crossley/ Mark Percy +44 20 7149 6000

 

About Amphion Innovations plc

Amphion (LSE: AMP) builds shareholder value in emerging companies in the medical and technology sectors, by using a focused, hands-on company building approach, based on decades of experience in both the US and UK. Amphion has significant shareholding in 7 Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies. The Partner Companies collectively own or control over 200 separately identified pieces of intellectual property, a number which grows rapidly each year.

 

On the web: www.amphionplc.com

 

About McCarter & English, LLP

McCarter & English, LLP, established more than 160 years ago, represents Fortune 500 and middle-market companies in their national, regional and local litigation and on important transactions. Its 400 attorneys are based in offices in Boston, Hartford, New York, Newark, Philadelphia, Stamford, and Wilmington. www.mccarter.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCDMMZMRMMGMZG
Date   Source Headline
22nd Dec 20177:01 amRNSComment on Polarean Fund Raise
22nd Dec 20177:00 amRNSRestructure of Loan and Additional Drawdown
5th Dec 20177:00 amRNSIssue of Shares
23rd Nov 20177:00 amRNSFurther Update on Polarean Imaging Limited
10th Nov 20177:00 amRNSUpdate on Polarean Imaging Limited
2nd Nov 20177:00 amRNSOrder Dismissing DataTern Case
11th Oct 20177:00 amRNSRelated Party Transaction
5th Oct 20177:00 amRNSPartner Company releases positive clinical results
29th Sep 20177:00 amRNSHalf-year Report
25th Sep 20177:01 amRNSHolding(s) in Company
25th Sep 20177:00 amRNSSale of Partner Company Shares
30th Aug 20177:00 amRNSSale of partner company shares
30th Aug 20177:00 amRNSHolding(s) in Company
1st Aug 20175:19 pmRNSAGM Statement
28th Jun 20177:00 amRNSFinal Results
31st May 20177:00 amRNSPartner Company m2m Imaging merger update
22nd May 20174:36 pmRNSAdditional Draw Down on Loan Facility
7th Feb 20177:00 amRNSAdditional Draw Down on Loan Facility
1st Feb 20175:18 pmRNSHolding(s) in Company
30th Dec 20162:38 pmRNSHolding(s) in Company
16th Dec 20163:07 pmRNSDirector/PDMR Shareholding
9th Dec 20163:50 pmRNSDirector/PDMR Shareholding
24th Nov 20162:15 pmRNSHolding(s) in Company
8th Sep 20167:00 amRNSRe-negotiated terms of Motif CPN
7th Sep 20167:00 amRNSInterim Results for the six months to 30 June 2016
22nd Aug 20163:58 pmRNSAdditional Draw Down on Loan Facility
3rd Aug 20164:13 pmRNSHolding(s) in Company
29th Jul 20167:00 amRNSResults of AGM and Directorate Change
18th Jul 20164:33 pmRNSTransfer of Shares
13th Jul 20167:01 amRNSNotice of Intention to List on NASDAQ by Motif Bio
13th Jul 20167:00 amRNSAdditional Draw Down on Loan Facility
23rd Jun 20167:00 amRNSFinal Results
29th Apr 20164:02 pmRNSAdditional Terms on Loan Facility
28th Apr 20167:00 amRNSAdditional Draw Down on Loan Facility
7th Apr 20167:00 amRNSAmphion settles contested arbitration ruling
3rd Mar 20167:00 amRNSConvertible Promissory Note Extended
7th Jan 20167:00 amRNSDirectors' Dealings
5th Jan 20167:00 amRNSConvertible Promissory Note Terms Extended
26th Nov 20157:00 amRNSAdditional Draw on Loan Facility
5th Nov 20157:00 amRNSPartner Company m2m Imaging Corp. to merge
30th Oct 20154:20 pmRNSDeath of a Director - Replacement
30th Oct 20153:50 pmRNSDeath of a Director
17th Sep 20157:00 amRNSAmphion to present in London
16th Sep 20157:00 amRNSDirectors' Dealings
10th Sep 20157:00 amRNSDataTern Receives Favourable Ruling
3rd Sep 20157:00 amRNSInterim Results
28th Aug 20159:08 amRNSHolding(s) in Company
7th Aug 20155:15 pmRNSResult of AGM
22nd Jul 20154:32 pmRNSFDA QIDP Designation
22nd Jul 20157:00 amRNSFinal condition of £22m placing satisfied

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.